Genomic analysis demonstrates lactylation gene signatures predict therapy response in hepatocellular carcinoma, suggesting strong utility as clinical biomarkers.
The lactylation-related model exhibited robust predictive efficiency in HCC. The glycolysis pathway was enriched in the HCC tumor samples. A low-risk score indicated better treatment response to most targeted drugs and immunotherapy. The lactylation-related gene signature could be used as a biomarker for the effective clinical treatment of HCC.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: